Decreased mitochondrial activity in the demyelinating cerebellum of progressive multiple sclerosis and chronic EAE contributes to Purkinje cell loss
- PMID: 40523174
- PMCID: PMC12207518
- DOI: 10.1073/pnas.2421806122
Decreased mitochondrial activity in the demyelinating cerebellum of progressive multiple sclerosis and chronic EAE contributes to Purkinje cell loss
Abstract
In multiple sclerosis (MS), cerebellar gray matter atrophy, white matter demyelination, and Purkinje cell (PC) loss have been linked to tremors, impaired motor control, and loss of coordination. Similar pathologies have been observed in the mouse model of MS, experimental autoimmune encephalomyelitis (EAE). This study hypothesized that inflammatory demyelination of the cerebellum alters overall mitochondrial function and is a contributor to axon degeneration and PC loss. Postmortem cerebellar tissue from MS patients, particularly those with secondary progressive MS, showed decreased mitochondrial complex IV (COXIV) activity and significant PC loss. Inflammation, PC axon demyelination, axon degeneration, and parallel fiber loss were also evident. These findings were mirrored in late-stage EAE mice, which also showed increased inflammation and demyelination, reduced PC COXIV activity, and overall PC loss. Further analysis of EAE mice revealed altered mitochondrial structure, modified mitochondrial respiration, and reduced levels of mitochondrial genes involved in energy production. These findings indicate that both human MS and mouse EAE share similar cerebellar changes linked to mitochondrial dysfunction. Thus, late-stage EAE is a valuable model for studying MS-related cerebellar pathology, and mitochondria may be a potential therapeutic target for MS treatment.
Keywords: COXIV; axon damage; cerebellar pathology; experimental autoimmune encephalomyelitis; mitochondria respiration.
Conflict of interest statement
Competing interests statement:The authors declare no competing interest.
Similar articles
-
Evaluating the Protective Effects of Silymarin Along with a Cholesterol-Supplemented Diet Against Demyelination in an EAE Mouse Model of Multiple Sclerosis: Lipidomic and Inflammatory Aspects.Mol Neurobiol. 2025 Aug;62(8):10182-10200. doi: 10.1007/s12035-025-04903-8. Epub 2025 Apr 7. Mol Neurobiol. 2025. PMID: 40193019
-
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
-
Cell therapy procedure using anti-inflammatory macrophage M2 can potentially reduce Clinical Score in animals with Experimental Autoimmune Encephalomyelitis: A preclinical systematic review and meta-analysis study.Fundam Clin Pharmacol. 2023 Apr;37(2):215-225. doi: 10.1111/fcp.12844. Epub 2022 Nov 14. Fundam Clin Pharmacol. 2023. PMID: 36300567
-
Ferritin loss in astrocytes reduces spinal cord oxidative stress and demyelination in the experimental autoimmune encephalomyelitis (EAE) model.Glia. 2024 Dec;72(12):2327-2343. doi: 10.1002/glia.24616. Epub 2024 Sep 3. Glia. 2024. PMID: 39228110
-
A novel combination approach to effectively reduce inflammation and neurodegeneration in multiple sclerosis models.Neurochem Int. 2024 May;175:105697. doi: 10.1016/j.neuint.2024.105697. Epub 2024 Feb 15. Neurochem Int. 2024. PMID: 38364938 Free PMC article.
References
-
- Weinshenker B. G., et al. , The natural history of multiple sclerosis: A geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114, 1057–1067 (1991). - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical